门冬胰岛素联合地特胰岛素治疗妊娠糖尿病的疗效分析

目的：探讨门冬胰岛素联合地特胰岛素治疗妊娠糖尿病的临床疗效。方法方便选择该院自2014年1月—2016年6月收治的74例妊娠糖尿病患者为研究对象,并按照随机数字表法分为对照组和观察组,每组各37例。对照组患者使用生物合成人胰岛素注射液治疗(三餐前30 min皮下注射),观察组患者接受门冬胰岛素(三餐前进食前皮下注射)+地特胰岛素(睡前皮下注射)治疗。比较两组患治疗前后空腹血糖(FBG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)、血糖达标时间及低血糖发生率差异。结果治疗前两组间FBG对照组和观察组分别为(9.57±3.24) mmol/L vs(9.54±2.68)mmol/L,t=0.526]、2 hPG对照组和观察组分别为(15.43±3.58)mmol/L vs(15.54±2.52)mmol/L,t=-0.632]和HbA1c对照组和观察组分别为(10.54±1.25)% vs(10.48±1.32)%,t=0.695]差异无统计学意义(P>0.05),治疗后两组FBG对照组和观察组分别为(6.78±2.15)mmol/L vs(5.43±1.64)mmol/L,t=0.3.423]、2 hPG对照组和观察组分别为(11.36±2.46)mmol/L vs(9.23±1.54)mmol/L,t=3.695]和HbA1c对照组和观察组分别为(7.65±1.54)%vs(6.23±1.63)%,t=3.452]较治疗前均明显降低,与治疗前相比差异无统计学意义(P<0.05),且观察组患者较对照组下降更为明显(与对照组治疗后相比,P<0.05)。治疗期间观察组患者血糖达标时间(6.24±1.43)d和低血糖发生率(5.41%)均明显低于对照组分别为(8.56±2.14)d、(18.9%)]患者,差异有统计学意义(t=3.562,χ2=3.446,P<0.05)。结论门冬胰岛素联合地特胰岛素治疗妊娠糖尿病临床效果显著,低血糖发生率低,值得在临床中推广应用。

Analysis of Insulin Aspart Insulin Detemir Treatment of Gestational Diabetes Mellitus

Objective To investigate the clinical efficacy of insulin aspart insulin detemir treatment of gestational diabetes mellitus. Methods Convenient selection 74 cases of gestational diabetes in our hospital from January 2014 to June 2016 were selected and divided into control group and observation group according to the random number table, 37 cases in each group. The control and treatment of adult patients using Neutrul Insulin Injection protamine (three before subcutaneous in-jection of 30min), the patients in the observation group received insulin aspart (meals intake before subcutaneous injection of insulin detemir before subcutaneous injection treatment. Compared the two groups before and after the treatment of fast-ing blood glucose (FBG), postprandial 2 h blood glucose (2 hPG), glycosylated hemoglobin (HbA1c), blood sugar compliance time and the incidence of hypoglycemia. Results Before treatment between the two groups of (9.57±3.24)mmol/L vs (9.54± 2.68)mmol/L,t=0.526]、2 hPG(15.43±3.58) mmol/L vs(15.54±2.52)mmol/L,t=-0.632] and HbA1c(10.54±1.25)% vs (10.48±1.32)%,t=0.695] showed no significant difference (P> 0.05), the two groups after treatment of FBG (6.78±2.15) mmol/L vs(5.43±1.64) mmol/L,t=0.3.423]、2 hPG(11.36±2.46)mmol/L vs(9.23±1.54)mmol/L,t=3.695] and HbA1c(7.65± 1.54)% vs (6.23±1.63)%,t=3.452]were significantly lower than before treatment, compared with before treatment, the dif-ference was not statistically significant (P < 0.05), and the patients in the observation group than the control group de-creased more significantly (compared with the control group after treatment were P< 0.05). During the treatment period, the time of reaching the standard(6.24±1.43)d and the incidence(5.41%)of hypoglycemia in the observation group were signifi-cantly lower than those in the control group(8.56±2.14)d、(18.9%)], and the difference was statistically significant (t=3.562 and χ2=3.446,P < 0.05). Conclusion Insulin aspart insulin detemir combined with significant clinical effect for the treat-ment of gestational diabetes, hypoglycemia, is worth popularizing in clinical application.